Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of ALKS 7119 in healthy adults
NL-OMON43047Phase 1Active, not recruiting
- Sponsor
- Alkermes
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ALKS 7119 in Alzheimer's disease (AD) and Dementia (2 arms), sponsored by Alkermes. Primary endpoint: Safety and tolerability. Started Jun 2016; status: active, not recruiting.
02
Drugs
ALKS 7119
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON43047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43047.